Cannabis in the management of PTSD : a systematic review, Yasir Rehman, Amreen Saini, Sarina Huang, Emma Sood, Ravneet Gill and Sezgi Yanikomeroglu AIMS Neuroscience, 2021, 8, (3), 414-434. Doi : 10.3934/Neuroscience.2021022 Abstract : Introduction : Existing reviews exploring cannabis effectiveness have numerous limitations including narrow search strategies. We systematically explored cannabis effects on PTSD symptoms, quality of life (QOL), and return to work (RTW). We also investigated harm outcomes such as adverse effects and dropouts due to adverse effects, inefficacy, and all-cause dropout rates. Methods : Our search in MEDLINE, EMBASE, PsycInfo, CINAHL, Web of Science, CENTRAL, and PubMed databases, yielded 1 eligible RCT and 10 [...]
Lire la suiteEndocannabinoid System as Therapeutic Target of PTSD : A Systematic Review Luca Steardo, Jr., Elvira Anna Carbone, Giulia Menculini, Patrizia Moretti, Luca Steardo and Alfonso Tortorella Life, 2021, 11, 214. Doi : 10.3390/life11030214 Abstract : Post-Traumatic Stress Disorder (PTSD) is a complex disorder involving dysregulation of stress-related hormones and neurotransmitter systems. Research focused on the endocannabinoid system (eCBS) for anxiety and stress regulation, cognitive and emotional responses modulation and aversive memories extinction, leading to the hypothesis that it could represent a possible alternative treatment target for PTSD. In this systematic review, we summarize evidence about the efficacy and safety of medicinal cannabidiol (CBD), D9-tetrahydrocannabinol (D9-THC), and [...]
Lire la suiteUse of Medicinal Cannabis and Synthetic Cannabinoids in Post-Traumatic Stress Disorder (PTSD) : A Systematic Review Laura Orsolini, Stefania Chiappini, Umberto Volpe, Domenico De Berardis, Roberto Latini, Gabriele Duccio Papanti and John Martin Corkery Medicina, 2019, 55, 525, 1-14 doi : 10.3390/medicina55090525 www.mdpi.com/journal/medicina Abstract : Background and Objectives : Post-traumatic stress disorder (PTSD) is a common psychiatric disorder resulting from a traumatic event, is manifested through hyperarousal, anxiety, depressive symptoms, and sleep disturbances. Despite several therapeutic approaches being available, both pharmacological and psychological, recently a growing interest has developed in using cannabis and synthetic cannabinoids stems from their consideration as more efficient and better tolerated alternatives [...]
Lire la suiteCirculating endocannabinoids and genetic polymorphisms as predictors of posttraumatic stress disorder symptom severity : heterogeneity in a community-based cohort Terri A. deRoon-Cassini, Carisa L. Bergner, Samantha A. Chesney, Nicholas R. Schumann, Tara Sander Lee, Karen J. Brasel and Cecilia J. Hillard Translational Psychiatry, 2022, 12, 48, 1-12. Doi : 10.1038/s41398-022-01808-1 The endocannabinoid signaling system (ECSS) regulates fear and anxiety. While ECSS hypoactivity can contribute to symptoms of established post-traumatic stress disorder (PTSD), the role of the ECSS in PTSD development following trauma is unknown. A prospective, longitudinal cohort study of 170 individuals (47% non-Hispanic Caucasian and 70% male) treated at a level 1 trauma [...]
Lire la suiteBibliographie : Cannabinoïdes et PTSD Docteur Christian Sueur, GRECC, mars 2022
Lire la suitePsilocybin, in 10 mg or 25 mg doses, has no short- or long-term detrimental effects in healthy people Patrick O'Brien King’s College London News Center, 2022 https://www.kcl.ac.uk/news/psilocybin-in-10mg-or-25mg-doses-has-no-short-or-long-term-detrimental-effects-in-healthy-people Psilocybin can be safely administered at doses of either 10mg or 25mg to up to six participants simultaneously. New research from the Institute of Psychiatry, Psychology, & Neuroscience (IoPPN) at King’s College London, in partnership with COMPASS Pathways, has established that psilocybin can be safely administered at doses of either 10mg or 25mg to up to six participants simultaneously. The research, published in The Journal of Psychopharmacology, is an essential first step in demonstrating the safety and feasibility of [...]
Lire la suiteCannabidiol as a Therapeutic Alternative for Post-traumatic Stress Disorder : From Bench Research to Confirmation in Human Trials Rafael M. Bitencourt and Reinaldo N. Takahashi Frontiers in Neuroscience, 2018, 12, 502, 1-10. Doi : 10.3389/fnins.2018.00502 Post-traumatic stress disorder (PTSD) is characterized by poor adaptation to a traumatic experience. This disorder affects approximately 10% of people at some point in life. Current pharmacological therapies for PTSD have been shown to be inefficient and produce considerable side effects. Since the discovery of the involvement of the endocannabinoid (eCB) system in emotional memory processing, pharmacological manipulation of eCB signaling has become a therapeutic possibility for the treatment of [...]
Lire la suiteIntegrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder Matthew N. Hill, Patrizia Campolongo, Rachel Yehuda and Sachin Pate Neuropsychopharmacology REVIEWS, 2018, 43, 80–102. doi : 10.1038/npp.2017.162 Exposure to stress is an undeniable, but in most cases surmountable, part of life. However, in certain individuals, exposure to severe or cumulative stressors can lead to an array of pathological conditions including posttraumatic stress disorder (PTSD), characterized by debilitating trauma-related intrusive thoughts, avoidance behaviors, hyperarousal, as well as depressed mood and anxiety. In the context of the rapidly changing political and legal landscape surrounding use of cannabis products in the USA, [...]
Lire la suiteShort and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder Emily M. LaFrance, Nicholas C. Glodosky, Marcel Bonn-Miller, Carrie Cuttler Journal of Affective Disorders, 2020, 274, 298–304 Doi : 10.1016/j.jad.2020.05.132 A B S T R A C T Background : Many individuals use cannabis to manage symptoms of post-traumatic stress disorder (PTSD), and evidence indicates that the endocannabinoid system represents a viable target for treating these symptoms. Method : Data from 404 medical cannabis users who self-identified as having PTSD were obtained from Strainprint®, a medical cannabis app that patients use to track changes in symptoms as a function of different strains and doses [...]
Lire la suiteCannabidiol has a unique effect on global brain activity: a pharmacological, functional MRI study in awake mice Aymen H. Sadaka, Ana G. Ozuna1, Richard J. Ortiz, Praveen Kulkarni, Clare T. Johnson, Heather B. Bradshaw, Bruce S. Cushing, Ai‑Ling Li, Andrea G. Hohmann and Craig F. Ferris Journal of Translationnal Medicine, 2021, 19, 220, 1-16. Doi : 10.1186/s12967-021-02891-6 Abstract Background : The phytocannabinoid cannabidiol (CBD) exhibits anxiolytic activity and has been promoted as a potential treatment for post-traumatic stress disorders. How does CBD interact with the brain to alter behavior? We hypothesized that CBD would produce a dose-dependent reduction in brain activity and functional coupling in [...]
Lire la suite